L. Boyken

In Vitro Susceptibility of Invasive Isolates of <i>Candida</i> spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance

Michael A. Pfaller, L. Boyken, R. J. Hollis et al. · Journal of Clinical Microbiology · 2007 · 385 citations · Full text

Microbial Pathogens, Vitro Susceptibility, Clinical Mycology +16

The changing epidemiology of healthcare-associated candidemia over three decades

Daniel J. Diekema, Sophie Arbefeville, L. Boyken et al. · Diagnostic Microbiology and Infectious Disease · 2012 · 316 citations

Diagnostic Mycology, Healthcare-associated Candidemia, Clinical Epidemiology +5

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

Michael A. Pfaller, S. A. Messer, L. Boyken et al. · Diagnostic Microbiology and Infectious Disease · 2004 · 235 citations

Antifungal Agent, Pathogenic Microbiology, Antifungal Agents +11

Global Trends in the Antifungal Susceptibility of <i>Cryptococcus neoformans</i> (1990 to 2004)

Michael A. Pfaller, S. A. Messer, L. Boyken et al. · Journal of Clinical Microbiology · 2005 · 204 citations · Full text

Pathogenic Microbiology, Clinical Laboratory Standards, Clinical Mycology +16

In Vitro Susceptibilities of <i>Candida</i> spp. to Caspofungin: Four Years of Global Surveillance

Michael A. Pfaller, L. Boyken, R. J. Hollis et al. · Journal of Clinical Microbiology · 2006 · 193 citations · Full text